<DOC>
	<DOC>NCT01226745</DOC>
	<brief_summary>The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 [NCT01081782]).</brief_summary>
	<brief_title>Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Completed 26 weeks of doubleblind phase of Study ONO4641POU006 Presence of any dermatological abnormalities during Study ONO4641POU006 that could increase the risk of the patient developing a skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>ONO-4641</keyword>
	<keyword>MSC2430913A</keyword>
	<keyword>Efficacy</keyword>
</DOC>